thumbnail image
ABOUT USCOVID19 Test
CHALLENGE & SOLUTION  
  • DRY CLINICAL CHEMISTRY
  • RAPID DIAGNOSTICS SYSTEM
  • FECAL IMMUNOCHEMICAL TEST
REFERENCE CENTERVETERINARYFUJIFILM's HISTORY
ABOUT USCOVID19 Test
CHALLENGE & SOLUTION  
  • DRY CLINICAL CHEMISTRY
  • RAPID DIAGNOSTICS SYSTEM
  • FECAL IMMUNOCHEMICAL TEST
REFERENCE CENTERVETERINARYFUJIFILM's HISTORY
  • Login
  • ABOUT USCOVID19 Test
    CHALLENGE & SOLUTION  
    • DRY CLINICAL CHEMISTRY
    • RAPID DIAGNOSTICS SYSTEM
    • FECAL IMMUNOCHEMICAL TEST
    REFERENCE CENTERVETERINARYFUJIFILM's HISTORY
    ABOUT USCOVID19 Test
    CHALLENGE & SOLUTION  
    • DRY CLINICAL CHEMISTRY
    • RAPID DIAGNOSTICS SYSTEM
    • FECAL IMMUNOCHEMICAL TEST
    REFERENCE CENTERVETERINARYFUJIFILM's HISTORY
    ABOUT USCOVID19 Test
    CHALLENGE & SOLUTION  
    • DRY CLINICAL CHEMISTRY
    • RAPID DIAGNOSTICS SYSTEM
    • FECAL IMMUNOCHEMICAL TEST
    REFERENCE CENTERVETERINARYFUJIFILM's HISTORY
  • Login
    • Fecal Immunochemical Test (FIT)

       

      FIGHTING AGAINST

      COLORECTAL CANCER

      EARLY DETECTION IS KEY TO FIGHT AGAINST COLORECTAL CANCER,

      the #2 COMMON CANCER IN EUROPE.

    • WHAT YOU NEED TO KNOW

       

      • Colorectal cancer is #2 common cause of cancer related death in Europe (#2 common cancer in Women after Breast Cancer. #3 most common cancer in Men after lung and prostate Cancer.)
      • 1 in 20 individuals born today will be diagnosed with Colorectal cancer in the life and 1 person will die of Colorectal Cancer in every 2 minutes in Europe.
      • The five years survival rate is 90% if diagnosed at the early stage so the early detection is really important. 

      Resource: WHO/Europe

    • THE CHALLENGES OF HEALTH CARE SETTING

       

      • Several screening options exist for the early detection of colorectal cance such as the fecal occult blood test, flexible sigmoidoscopy, colonoscopy and computed tomographic colonography. 
      • The European Union recommends FOBT screening for colorectal cancer in men and women aged 50 to 74. 
      • Colorectal cancer risk varies across Europe so the benefit of screening will also vary, however with a high-quality screening programme and sufficient participation, mortality reduction can be anticipated in all countries.
       Resource: WHO/Europe

    • OUR SOLUTION

      Comprehensive Solution for Colorectal Cancer Screening: FIT, Colonoscopy and Screening Management System

       

      CLICK IMAGES to go to Product Page

      FOBIT FWIII

      High throughput FIT system

      High throughput FIT system using gold colloidal reaction technology. Throughput: 250 test/hour.

       

      Click the image to go to Product page.

      QUICK RUN II

      A bench-top size FIT system

      A bench top semi-automated FIT analyzer for small facilities.

      Throughput: 60 test/hour.

       

      Click the image to go to Product page.

      SYNAPSE CWM-ES

      Screening management system

      Screening management system covering not only FIT result but also include the report and image from Colonoscopy exams.

      COLONOSCOPE

      ELUXEO 700 series

      ELUXEO™ 700 series endoscopes for upper and lower GI.

       
       

      Click the image to go to Fujifilm's website

    • IMAGE: Workflow of Colorectal Cancer Screening (*) and where Fujifilm has the solution for

      (*) The workflow of Colorectal Cancer Screening may differ country by country.

    • OTHER SOLUTION

      See FUJIFILM's wide range of IVD Solution for Healthcare Settings

      DRY CLINICAL CHEMISTRY

      RAPID DIAGNOSTICS SYSTEM

    •  

      Check all News, Videos and Brochure

       

      GO TO REFERENCE CENTER
    • CONTACT US

      Interested? Contact us for more information.

      FUJIFILM EUROPE
      HEESEN STR 31, DUSSELDORF, GERMANY
      nozomi.sekine@fujifilm.com
      Submit

    © 2021

    Privacy Policy     Terms & Conditions     Imprint

      Home
      Contact
    All Posts
    ×
    Cookie Use
    We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
    Learn More